Transforming growth factor alpha immunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic liver tissue

Imagem de Miniatura
Arquivos
art_AVANCINI-ALVES_Transforming_growth_factor_alpha_immunoreactivity_A_study_in_2012_eng.pdf (91.26 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2012
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MEXICAN ASSOC HEPATOLOGY
Autores
PANNAIN, Vera Lucia
MORAIS, Jose Rodrigo
DAMASCENO-RIBEIRO, Osmar
Citação
ANNALS OF HEPATOLOGY, v.11, n.4, p.495-499, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Transforming growth factor alpha (TGF alpha) is an important mitogen that binds to epidermal growth factor receptor and is associated with the development of several tumors. Aims. Assessment of the immunoexpression of TGF alpha in hepatocellular carcinoma (HCC) and in non-neoplastic liver tissue and its relationship to morphological patterns of HCC. Material and methods. The immunohistochemical expression of TGF alpha was studied in 47 cases of HCC (27 multinodular, 20 nodular lesions). Five lesions measured up to 5 cm and 15 lesions above 5 cm. Thirty-two cases were graded as I or II and 15 as III or IV. The non-neoplastic tissue was examined in 40 cases, of which 22 had cirrhosis. HBsAg and anti-HCV were positive in 5/38 and 15/37 patients, respectively. The statistical analysis for possible association of immunostaining of TGF alpha and pathological features was performed through chi-square test. Results. TGF alpha was detected in 31.9% of the HCC and in 42.5% of the non-neoplastic. There was a statistically significant association between the expression of TGF alpha and cirrhosis (OR = 8.75, 95% CI = [1.93, 39.75]). The TGF alpha was detected more frequently in patients anti-HCV(+) than in those HBsAg(+). The immunoexpression of TGF alpha was not found related to tumor size or differentiation. In conclusion the TGF alpha is present in hepatocarcinogenesis in HBV negative patients. Further analysis is needed to examine the involvement of TGF alpha in the carcinogenesis associated with HCV and other possible agents. In addition, TGF alpha has an higher expression in hepatocyte regeneration and proliferation in cirrhotic livers than in HCC.
Palavras-chave
Hepatocellular carcinoma, TGF alpha, Immunohistochemical, Liver
URI
https://observatorio.fm.usp.br/handle/OPI/951
Referências
  1. Baek JY, 2010, INT J CANCER, V127, P1060, DOI 10.1002/ijc.25127
  2. Calvisi DF, 2005, TOXICOL PATHOL, V33, P181, DOI 10.1080/01926230590522095
  3. Chagas AL, 2009, BRAZ J MED BIOL RES, V42, P958, DOI 10.1590/S0100-879X2009005000019
  4. CHUANG LY, 1991, HEPATOLOGY, V13, P1112, DOI 10.1016/0270-9139(91)92481-M
  5. Chung YH, 2000, CANCER, V89, P977, DOI 10.1002/1097-0142(20000901)89:5<977::AID-CNCR6>3.0.CO;2-I
  6. COLLIER JD, 1993, LIVER, V13, P151
  7. Doraiswamy V, 2000, BIOL REPROD, V63, P789, DOI 10.1095/biolreprod63.3.789
  8. Edmonson HA, 1952, CANCER, V7, P462
  9. Fartoux L, 2006, GASTROEN CLIN BIOL, V30, P1133, DOI 10.1016/S0399-8320(06)73490-X
  10. Fassio E, 2010, ANN HEPATOL, V9, P63
  11. HSIA CC, 1992, CANCER, V70, P1049, DOI 10.1002/1097-0142(19920901)70:5<1049::AID-CNCR2820700507>3.0.CO;2-C
  12. Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709
  13. Kiss A, 1997, CLIN CANCER RES, V3, P1059
  14. Kitisin K, 2007, GASTROINTEST CANC S2, V1, P13
  15. Kojiro M, 2005, SEMIN LIVER DIS, V25, P133, DOI 10.1055/s-2005-871193
  16. Lachenmayer A, 2010, DIG LIVER DIS S, V42S, P264
  17. LIU C, 1988, CANCER RES, V48, P850
  18. Masuhara M, 1996, HEPATOLOGY, V24, P323, DOI 10.1002/hep.510240207
  19. MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558
  20. MORIMITSU Y, 1995, HUM PATHOL, V26, P1126, DOI 10.1016/0046-8177(95)90275-9
  21. Nalesnik LA, 1998, HUM PATHOL, V29, P228
  22. Nascimento C, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-51
  23. Nordenstedt Helena, 2010, Dig Liver Dis, V42 Suppl 3, pS206, DOI 10.1016/S1590-8658(10)60507-5
  24. Saffroy R, 2004, ANN BIOL CLIN-PARIS, V62, P649
  25. Severi T, 2010, ACTA PHARMACOL SIN, V31, P1409, DOI 10.1038/aps.2010.142
  26. Tanaka S, 1996, DIGEST DIS SCI, V41, P208, DOI 10.1007/BF02208606
  27. TANAKA S, 1991, AM J PATHOL, V139, P123
  28. Theise ND, 2011, WHO CLASSIFICATION T, P205
  29. Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
  30. TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258
  31. Tomiya T, 1996, CANCER, V77, P1056, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1056::AID-CNCR8>3.0.CO;2-F
  32. TWARDZIK DR, 1985, CANCER RES, V45, P5413
  33. Yao DF, 2007, HEPATOB PANCREAT DIS, V6, P241
  34. YEH J, 1989, BIOMED PHARMACOTHER, V43, P651, DOI 10.1016/0753-3322(89)90083-8
  35. Yeh MM, 2007, AM J SURG PATHOL, V31, P681, DOI 10.1097/PAS.0b013e31802ff7aa
  36. Zhang J, 2004, WORLD J GASTROENTERO, V10, P830

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14